Skip to main content

Enzymatica appoints acting CEO

Press Release   •   Sep 09, 2014 09:44 GMT

Enzymatica’s Chairman Christian W. Jansson is today taking over as acting CEO of Enzymatica until a permanent successor has been recruited.

Michael Edelborg Christensen has decided to leave Enzymatica after five years in the company. The process of recruiting a new CEO will begin immediately.

- Enzymatica thank Michael for a fantastic job during his years in the company. His dedication and drive have been very important for the company's positive development. The Board and CEO have different views on strategic issues and Michael therefore chooses to leave the company. We respect his decision and wish him well in the future. The company's expansion plans to invest in more markets and new products remain unchanged, says Christian W. Jansson.

Christian W. Jansson has served as the company's Chairman of the Board since May 2013 and has good insight in the company. Christian has extensive experience in both small and large growth companies, and retail, including from his time as President and CEO of KappAhl AB and Ellos AB. He serves on the board of several companies, including Apoteket AB, EuroPrice AS, KappAhl AB and Vivoline Medical AB. In Enzymatica he remains as Chairman.


For more information, please contact:
Christian W Jansson, Chairman of the Board and acting CEO Enzymatica AB
Phone: +46 706 37 12 58. E-mail: ir@enzymatica.se

Tina Dackemark Lawesson, Senior Communications Officer Enzymatica AB
Phone: +46 286 31 00. E-mail: tina.lawesson@enzymatica.se

About Enzymatica AB (publ)

Enzymatica AB (publ) develops and sells medical technology products based on an enzyme from deep-sea cod. Our development includes medical devices in upper respiratory infections and oral health, and veterinary products in oral health and dermatology. The launched medical portfolio includes ColdZyme® against common colds. It is headquartered in Lund, Sweden, and is listed on Aktietorget. For more information, please visit www.enzymatica.com.

Comments (0)

Add comment

Comment